| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Merck & Co., Inc. | 20% | $105,531,938 | 63,004,142 | Merck & Co., Inc. | 31 Jan 2025 |
As of 30 Sep 2025, 2 institutional investors reported holding 1,214,128 shares of Evaxion Biotech A/S - American Depositary Shares, each representing fifty Ordinary Shares, DKK 0.25 nominal value per share (EVAX). This represents 0.38% of the company’s total 315,652,014 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 1,214,128 | $4,565,121 | $3.63 | 2 | |
| 2025 Q2 | 1,214,128 | $2,974,613 | $2.22 | 2 | |
| 2025 Q1 | 1,214,128 | $2,246,136 | +$1,019,666 | $1.68 | 2 |
| 2024 Q4 | 806,483 | $681,502 | -$277,603 | $0.85 | 9 |
| 2024 Q3 | 548,474 | $1,705,753 | +$291,174 | $3.11 | 8 |
| 2024 Q2 | 453,337 | $1,313,498 | +$206,103 | $2.89 | 6 |
| 2024 Q1 | 381,029 | $1,219,293 | +$1,212,436 | $3.20 | 6 |
| 2023 Q4 | 10,000 | $6,857 | +$6,857 | $0.69 | 1 |